---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-017879"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:25:55.904499+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated

## Summary
- Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.
- Cash, cash equivalents, and marketable securities of $1,903.8M, up from $1,695.7M a year earlier.
- Over 50 authorized treatment centers activated globally for CASGEVY; >50 patients have had cells collected.
- R&D expenses fell to $82.2M in Q4 2024 from $95.1M in Q4 2023.
- Pipeline catalysts in 2025: CTX112 updates mid-2025; CTX310/320 updates H1 2025.

## SEC filing metadata
- accession: 0000950170-25-017879
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017879/0000950170-25-017879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017025017879/crsp-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-017879
- JSON: https://secwatch.observer/filing/0000950170-25-017879.json
- Plain text: https://secwatch.observer/filing/0000950170-25-017879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.